南通大学附属第三医院2017—2019年核苷(酸)类似物抗乙型肝炎病毒药物使用情况分析  

Analysis on the use of nucleoside(acid) analogues against hepatitis B virus drugs in the Third Affiliated Hospital of Nantong University from 2017 to 2019

作　　者：陆群[1] LU Qun(The third Affiliated Hospital of Nantong University,Nantong 226000,China)

机构地区：[1]南通大学附属第三医院,江苏省南通市226000

出　　处：《临床合理用药杂志》2020年第33期17-20,24,共5页Chinese Journal of Clinical Rational Drug Use

基　　金：江苏省南通卫健委青年医学人才科研基金项目(WR2017011)。

摘　　要：目的分析南通大学附属第三医院2017—2019年核苷(酸)类似物抗乙型肝炎病毒药物使用情况。方法收集南通大学附属第三医院2017—2019年使用的抗HBV的核苷(酸)类似物相关资料,分析2017—2019年各核苷(酸)类似物使用量、用药频度(DDDs)及增值。结果 2017—2019年阿德福韦和替比夫定使用量逐年下降,拉米夫定使用量在2018年上升后下降,而恩替卡韦和替诺福韦的使用量逐年上升。阿德福韦和替比夫定的DDDs呈逐年下降趋势,拉米夫定在2019年也开始下降,恩替卡韦和替诺福韦的增长趋势明显。结论核苷(酸)类似物已成为治疗乙肝的重要药物,在临床治疗中应根据不同患者的情况区别用药,优化治疗体系,指导临床用药。Objective To analyze the use of nucleoside(acid) analogues against hepatitis B virus in the Third Affiliated Hospital of Nantong University from 2017 to 2019.Methods To collect the related data of anti-HBV nucleoside(acid) analogues used in the Third Affiliated Hospital of Nantong University from 2017 to 2019. To analyze the usage amount,DDDs and increment of nucleoside analogues from 2017 to 2019.Results From 2017 to 2019,the consumption of adefovir and telbivudine decreased year by year,the consumption of lamivudine decreased after rising in 2018,and the consumption of entecavir and tenofovir increased year by year.Conclusion Nucleoside(acid) analogues have become an important drug for the treatment of hepatitis B. In clinical treatment,different drugs should be used according to the situation of different patients,and the treatment system should be optimized to guide clinical drug use.

关 键 词：乙肝病毒 核苷(酸)类似物 用药调查 

分 类 号：R95[医药卫生—药学]